Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

T cell receptors recognizing hla-a1- or hla-cw7-restricted mage

a technology of t-cell receptors and mage, which is applied in the direction of immunoglobulins, peptides, drugs, etc., can solve the problems that patients without hla-a2 expression cannot be treated with t-cells, and hinder the widespread application of adoptive cell therapy

Inactive Publication Date: 2014-12-25
US DEPT OF HEALTH & HUMAN SERVICES
View PDF6 Cites 21 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent is about a new method for treating or preventing cancer in humans. This method involves using specific proteins, called TCRs, and administering them to a patient in a therapeutic amount. The TCRs work by targeting cancer-specific molecules and attacking them, which is effective in treating or preventing cancer in the patient. This patent covers all the methods and compositions needed to use TCRs for cancer treatment.

Problems solved by technology

However, patients that lack HLA-A2 expression cannot be treated with T-cells that target HLA-A2 restricted T-cell epitopes.
Such a limitation creates an obstacle to the widespread application of adoptive cell therapy.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
  • T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
  • T cell receptors recognizing hla-a1- or hla-cw7-restricted mage

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0115]This example demonstrates the cloning of TCR genes from T cell clones and the generation of TCR constructs.

[0116]Four T cell clones were initially identified that recognized epitopes of the MAGE-A gene family in the context of the dominant class I alleles HLA-A*01 and C*07. Approximately 30% of the melanoma patient population expresses HLA-A*01, and more than 95% of HLA-A*01+ individuals express the HLA-A*0101 sub-type, while more than 50% of melanoma patients express one of the two dominant HLA-C*07 sub-types, C*07:01 and C* 07:02.

[0117]The expressed TCR α and β chains were isolated from two clones, A10 and 13-18, that recognized residues 168-176 of protein MAGE-A3 (MAGE-A3:168-176) in the context of HLA-A*01. In addition, HLA-C*07 restricted TCRs recognizing a peptide corresponding to residues 170-178 of the MAGE-A12 protein (MAGE-A12:170-178) were isolated from clones 502 and FM8.

[0118]The α and β chains encoding functional TCRs were isolated from two MAGE-A12 reactive, HLA...

example 2

[0120]This example demonstrates the reactivity of cells expressing anti-MAGE-A3 TCR-A10 (SEQ ID NOs: 13 and 14) and anti-MAGE-A3 TCR 13-18 (SEQ ID NOs: 24 and 25) in response to HLA-A1+ / MAGE-A3+ cells.

[0121]Anti-CD3 stimulated T cells transduced with TCR-A10 (SEQ ID NO: 46) and TCR 13-18 (SEQ ID NO: 48) were evaluated for their ability to recognize a panel of HLA-A*01+melanoma cell lines that express MAGE-A3. Untransduced (UT) and transduced cells were co-cultured overnight with various tumor cell lines (Tables 1A, 1B and FIG. 6A), and interferon-gamma (IFN-γ) (pg / ml) was measured.

TABLE 1ATumorHLA-A*01Copies MAGE-A31860 mel+12,100397 mel+32,700SK23 mel+18,4002984 mel+14,9002951 mel+12,300A375 mel+3,670537 mel+4,2701300-A1 mel+7,2801300 mel—13,6002661 RCC+

TABLE 1BTumorHLA-A*01MAGE-A32984 mel++397 mel++2630 mel++2556 mel++526 mel—+624 mel—+2359 mel—+2661 RCC+—

[0122]The results indicate that six of the eight HLA-A*01+ / MAGE-A3+ melanoma cell lines that were evaluated stimulated higher l...

example 3

[0129]This example demonstrates the reactivity of cells expressing anti-MAGE-A12 TCR 502 (SEQ ID NOs: 34 and 35) or anti-MAGE-A12 TCR FM8 (SEQ ID NOs: 44 and 45) in response to co-culture with HLA-Cw*07+ / MAGE-A12+ cells.

[0130]Anti-CD3 stimulated CD8+ T cells isolated from two patient PBMC samples were transduced with a control construct encoding the truncated human low affinity nerve growth factor receptor (NGFR), TCR 502 (SEQ ID NO: 47), or TCR FM8 (SEQ ID NO: 49) were evaluated for their ability to recognize a panel of Cw*07+ melanoma cell lines that express MAGE-A 12.

[0131]Expression of the MAGE-A12 gene product was evaluated by Q-PCR using two primers (SEQ ID NOs: 61 and 62) designed to specifically amplify the MAGE-A12 gene product but not other members of the MAGE-A gene family as well as a MAGE-A12 specific probe (SEQ ID NO: 63). Antigen expression was determined using plasmid controls as standards for estimating copy numbers and using glyceraldehyde 3-phosphate dehydrogenase...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Antigenicityaaaaaaaaaa
Login to View More

Abstract

The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a) melanoma antigen family A (MAGE A)-3 in the context of HLA-A1 or b) MAGE-A12 in the context of HLA-Cw7. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.

Description

CROSS-REFERENCE TO RELATED APPLICATION[0001]This application claims priority to U.S. Application No. 61 / 535,086, filed on Sep. 15, 2011, which is incorporated by reference herein in its entirety.INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY[0002]Incorporated by reference in its entirety herein is a computer-readable nucleotide / amino acid sequence listing submitted concurrently herewith and identified as follows: One 52,162 Byte ASCII (Text) file named “710922ST25.TXT,” dated Aug. 22, 2012.BACKGROUND OF THE INVENTION[0003]Adoptive cell therapy (ACT) involves the transfer of reactive T cells into patients, including the transfer of tumor-reactive T cells into cancer patients. Adoptive cell therapy using T-cells that target human leukocyte antigen (HLA)-A2 restricted T-cell epitopes has been successful in causing the regression of tumors in some patients. However, patients that lack HLA-A2 expression cannot be treated with T-cells that target HLA-A2 restricted T-cell ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/705G01N33/574C07K16/28
CPCC07K14/70503G01N33/574C07K16/2803C07K14/7051C07K16/2809G01N33/57407A61K38/00C07K2317/73C07K2318/20A61K39/464488A61K39/464486A61K39/4611A61K39/4632A61P35/00A61P35/02A61K2039/5158A61K39/00
Inventor ROBBINS, PAUL F.ROSENBERG, STEVEN A.ZHU, SHIQUIFELDMAN, STEVEN A.MORGAN, RICHARD A.
Owner US DEPT OF HEALTH & HUMAN SERVICES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com